Health Canada has banned a handful of drugs coming from a Hospira sterile manufacturing facility in Italy after the reliability of lab data was called into question by the U.S. FDA in months prior.
Hospira, which was acquired by Pfizer in February for $17 billion, received a U.S. FDA warning letter in March detailing violations at its plant in Liscate, Italy. The U.S. regulator has not restricted the production or shipment of products from the facility.
According to the Canadian regulator, its ban includes all non-medically necessary products made at the plant, which includes Hospira's nausea treatments and injectable vitamins manufactured for AbbVie
Read the WSJ press release